Transcode Therapeutics, Inc. (RNAZ) company profile
Close on Nov 17, 2026Market cap $1.43MP/E –Yield –
About Transcode Therapeutics
Pharmaceutical Preparations, SIC 2834
TransCode is a clinical-stage biotechnology company that develops immuno-oncology and RNA-targeted therapeutics for the treatment of high-risk, advanced, and metastatic cancers. The company utilizes its proprietary TTX modular drug design engine to create delivery vehicles for synthetic oligonucleotides targeting genetic elements outside the liver. Its product candidates include TTX-MC138, an antisense inhibitor targeting microRNA-10b for solid tumors, alongside preclinical programs TTX-siPDL1, TTX-RIGA, and TTX-siMYC. Through acquisitions and licensing, TransCode also develops Seviprotimut-L, a polyvalent vaccine for stage IIB and IIC melanoma, and an oncolytic adenovirus immunotherapy platform directed at solid tumors including muscle-invasive bladder cancer. Its pipeline serves cancer patients with high unmet medical needs.
The company conducts clinical and preclinical stage development, carrying out multicenter clinical trials in collaboration with research organizations such as the MD Anderson Cancer Center. It acquired subsidiary operations including Polynoma, LLC, which is located in San Diego, California. The text does not state the company's founding year, website, or overall corporate headquarters.
Summary of the business section of Transcode Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Transcode Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- 6 Liberty Square, #2382 02109
- Phone
- (857) 301-6857
- Website
- transcodetherapeutics.com
- Employees
- 12, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, East Brunswick, New Jersey
Stock & identifiers
- Ticker
- RNAZ
- Exchange
- Nasdaq
- IPO date
- Jul 9, 2021
- Shares outstanding
- 17M, Aug 10, 2026
- Public float
- $6.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-28 reverse, May 15, 2025; 1-for-33 reverse, Dec 4, 2024; 1-for-40 reverse, Jan 16, 2024; 1-for-20 reverse, May 23, 2023
- SEC CIK
- 1829635
- CUSIP
- 89357L402
- ISIN
- US89357L4023
- FIGI
- BBG00ZGYHV03
- Share class FIGI
- BBG00ZGYHVW8
- EIN
- 81-1065054
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thomas A. Fitzgerald | Chief Financial Officer, Director | 56,318 |
| John A. Tattory | Interim CFO | – |
| Jack E. Stover | Director | – |
| Elizabeth Czerepak | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Total | vs. prior year |
|---|---|---|---|---|
| Philippe P. Calais Chief Executive Officer | $123.81K | $250.00K | $373.81K | – |
| Thomas A. Fitzgerald Vice President, Chief Financial Officer, and former interim Chief Executive Officer | $480.00K | $589.62K | $1.07M | +12% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 9, 2021
- Offer price
- $4.00
- Securities offered
- 6,250,000
- Gross proceeds
- $25.00M
- Exchange
- Nasdaq
- First trading day
- Jul 8, 2021
- First-day close
- $4.000.0%
- Lock-up ends (est.)
- Jan 4, 2022
“The initial public offering price is $4.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of April 3, 2026, we had 12 employees, all of whom are full-time.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?